Targeting chemosensitizing doses of toremifene based on protein binding

Gregory T. Wurz, Vernon D. Emshoff, Michael W. DeGregorio, Valerie J. Wiebe

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Toremifene is currently being evaluated as a chemosensitizing agent in doxorubicin-resistant patients. Although concentrations of >2 μM reverse resistance in vitro, target concentrations required to reverse multidrug resistance (MDR) in vivo may be highly influenced by variables such as protein binding in serum. We examined the effects of high serum concentrations on the cellular accumulation of toremifene in an MDR MDA-MB-A-1 human breast-cancer cell line. We then examined the cellular accumulation of doxorubicin at various toremifene concentrations in 5%-100% serum. We also measured the concentrations of toremifene and its major metabolites in plasma specimens obtained from two patients receiving 360 mg/day for 5 days in a phase I study. Our results show that (1) high serum concentrations decrease toremifene accumulation, (2) toremifene concentrations of ≥2.5 μm enhance doxorubicin accumulation, and (3) patients achieve plasma toremifene concentrations of 10-15 μm following doses of 360 mg/day×5 days. Our findings suggest that in vivo toremifene concentrations well above those used to reverse resistance in vitro are required to overcome the effect of high serum-protein binding.

Original languageEnglish (US)
Pages (from-to)412-414
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Volume31
Issue number5
DOIs
StatePublished - Sep 1993
Externally publishedYes

Fingerprint

Toremifene
Protein Binding
Doxorubicin
Multiple Drug Resistance
Serum
Plasmas
Metabolites
Blood Proteins
Cells
Breast Neoplasms
Cell Line

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Targeting chemosensitizing doses of toremifene based on protein binding. / Wurz, Gregory T.; Emshoff, Vernon D.; DeGregorio, Michael W.; Wiebe, Valerie J.

In: Cancer Chemotherapy and Pharmacology, Vol. 31, No. 5, 09.1993, p. 412-414.

Research output: Contribution to journalArticle

Wurz, Gregory T. ; Emshoff, Vernon D. ; DeGregorio, Michael W. ; Wiebe, Valerie J. / Targeting chemosensitizing doses of toremifene based on protein binding. In: Cancer Chemotherapy and Pharmacology. 1993 ; Vol. 31, No. 5. pp. 412-414.
@article{ea085779b0574601b5f4cf9d6ee88a9d,
title = "Targeting chemosensitizing doses of toremifene based on protein binding",
abstract = "Toremifene is currently being evaluated as a chemosensitizing agent in doxorubicin-resistant patients. Although concentrations of >2 μM reverse resistance in vitro, target concentrations required to reverse multidrug resistance (MDR) in vivo may be highly influenced by variables such as protein binding in serum. We examined the effects of high serum concentrations on the cellular accumulation of toremifene in an MDR MDA-MB-A-1 human breast-cancer cell line. We then examined the cellular accumulation of doxorubicin at various toremifene concentrations in 5{\%}-100{\%} serum. We also measured the concentrations of toremifene and its major metabolites in plasma specimens obtained from two patients receiving 360 mg/day for 5 days in a phase I study. Our results show that (1) high serum concentrations decrease toremifene accumulation, (2) toremifene concentrations of ≥2.5 μm enhance doxorubicin accumulation, and (3) patients achieve plasma toremifene concentrations of 10-15 μm following doses of 360 mg/day×5 days. Our findings suggest that in vivo toremifene concentrations well above those used to reverse resistance in vitro are required to overcome the effect of high serum-protein binding.",
author = "Wurz, {Gregory T.} and Emshoff, {Vernon D.} and DeGregorio, {Michael W.} and Wiebe, {Valerie J.}",
year = "1993",
month = "9",
doi = "10.1007/BF00686157",
language = "English (US)",
volume = "31",
pages = "412--414",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Targeting chemosensitizing doses of toremifene based on protein binding

AU - Wurz, Gregory T.

AU - Emshoff, Vernon D.

AU - DeGregorio, Michael W.

AU - Wiebe, Valerie J.

PY - 1993/9

Y1 - 1993/9

N2 - Toremifene is currently being evaluated as a chemosensitizing agent in doxorubicin-resistant patients. Although concentrations of >2 μM reverse resistance in vitro, target concentrations required to reverse multidrug resistance (MDR) in vivo may be highly influenced by variables such as protein binding in serum. We examined the effects of high serum concentrations on the cellular accumulation of toremifene in an MDR MDA-MB-A-1 human breast-cancer cell line. We then examined the cellular accumulation of doxorubicin at various toremifene concentrations in 5%-100% serum. We also measured the concentrations of toremifene and its major metabolites in plasma specimens obtained from two patients receiving 360 mg/day for 5 days in a phase I study. Our results show that (1) high serum concentrations decrease toremifene accumulation, (2) toremifene concentrations of ≥2.5 μm enhance doxorubicin accumulation, and (3) patients achieve plasma toremifene concentrations of 10-15 μm following doses of 360 mg/day×5 days. Our findings suggest that in vivo toremifene concentrations well above those used to reverse resistance in vitro are required to overcome the effect of high serum-protein binding.

AB - Toremifene is currently being evaluated as a chemosensitizing agent in doxorubicin-resistant patients. Although concentrations of >2 μM reverse resistance in vitro, target concentrations required to reverse multidrug resistance (MDR) in vivo may be highly influenced by variables such as protein binding in serum. We examined the effects of high serum concentrations on the cellular accumulation of toremifene in an MDR MDA-MB-A-1 human breast-cancer cell line. We then examined the cellular accumulation of doxorubicin at various toremifene concentrations in 5%-100% serum. We also measured the concentrations of toremifene and its major metabolites in plasma specimens obtained from two patients receiving 360 mg/day for 5 days in a phase I study. Our results show that (1) high serum concentrations decrease toremifene accumulation, (2) toremifene concentrations of ≥2.5 μm enhance doxorubicin accumulation, and (3) patients achieve plasma toremifene concentrations of 10-15 μm following doses of 360 mg/day×5 days. Our findings suggest that in vivo toremifene concentrations well above those used to reverse resistance in vitro are required to overcome the effect of high serum-protein binding.

UR - http://www.scopus.com/inward/record.url?scp=0027476855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027476855&partnerID=8YFLogxK

U2 - 10.1007/BF00686157

DO - 10.1007/BF00686157

M3 - Article

C2 - 8431976

AN - SCOPUS:0027476855

VL - 31

SP - 412

EP - 414

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 5

ER -